אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; calcium chloride dihydrate; polysorbate 80; glycine; sodium chloride; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 1000 iu - injection, powder for - excipient ingredients: polysorbate 80; calcium chloride dihydrate; glycine; sodium chloride; sucrose; histidine - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 2000 iu - injection, powder for - excipient ingredients: glycine; histidine; sucrose; calcium chloride dihydrate; sodium chloride; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; sucrose; glycine; calcium chloride dihydrate; histidine; sodium chloride - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - damoctocog alfa pegol, quantity: 3000 iu - injection, powder for - excipient ingredients: calcium chloride dihydrate; sucrose; sodium chloride; glycine; histidine; polysorbate 80 - jivi, damoctocog alfa pegol, is a long-acting recombinant factor viii concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? per-operative management of bleeding (surgical prophylaxis),jivi does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 500 [iu];   - injection with diluent - 500 iu - active: octocog alfa 500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1500 [iu];   - injection with diluent - 1500 iu - active: octocog alfa 1500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 1500 [iu];   - powder for infusion - 1500 iu - active: efmoroctocog alfa 1500 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.

ניו זילנד - אנגלית - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - efmoroctocog alfa 500 [iu];   - powder for infusion - 500 iu - active: efmoroctocog alfa 500 [iu]   excipient: calcium chloride dihydrate histidine polysorbate 20 sodium chloride sucrose water for injection - eloctate is a long-acting antihaemophilic factor (recombinant) indicated in adults and children with haemophilia a (congenital factor viii deficiency) for: · control and prevention of bleeding episodes · routine prophylaxis to prevent or reduce the frequency of bleeding episodes · perioperative management (surgical prophylaxis). eloctate does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand's disease.